Manufacturers submit marketing authorisation application for sotorasib to European Medicines Agency

Sotorasib, an investigational KRASG12C inhibitor. The application is for the treatment of adult patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer and is supported by data from phase 2 studies currently.

Source:

Biospace Inc.